Get the Stockscreener App
0.1126
6.94%
-0.0084
Pre-market:
.11
-0.0026
-2.31%
Incannex Healthcare Inc stock is traded at $0.1126, with a volume of 1.00M.
It is down -6.94% in the last 24 hours and down -86.58% over the past month.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
See More
Previous Close:
$0.121
Open:
$0.118
24h Volume:
1.00M
Relative Volume:
1.53
Market Cap:
$3.66M
Revenue:
-
Net Income/Loss:
$-21.91M
P/E Ratio:
-0.0756
EPS:
-1.49
Net Cash Flow:
-
1W Performance:
-15.27%
1M Performance:
-86.58%
6M Performance:
-95.94%
1Y Performance:
-95.40%
1-Day Range:
$0.1119
$0.125
1-Week Range:
$0.1119
$0.145
52-Week Range:
$0.1119
$3.55
Incannex Healthcare Inc Stock (IXHL) Company Profile
Name
Incannex Healthcare Inc
Sector
Phone
61 409 840 786
Address
401 DOCKLANDS DRIVE, DOCKLANDS, VICTORIA
Compare IXHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
0.1126 | 3.66M | 0 | -21.91M | 0 | -1.49 |
|
ZTS
Zoetis Inc
|
161.69 | 69.43B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.27 | 47.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.57 | 46.56B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.07 | 20.71B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.00 | 13.25B | 2.76B | 1.11B | 898.10M | 22.77 |
Incannex Healthcare Inc Stock (IXHL) Latest News
Incannex Healthcare Inc [IXHL] Revenue clocked in at $0.10 million, down -92.83% YTD: What’s Next? - dbtnews.com
It makes sense and dollars to buy Incannex Healthcare Inc (IXHL) stock - Sete News
Analyzing the Impact of Earnings Reports on Incannex Healthcare Inc Inc. (IXHL) Price Performance - investchronicle.com
Is Incannex Healthcare Inc (NASDAQ:IXHL) stock a better investment at this time? - uspostnews.com
Trading Day Review: Incannex Healthcare Inc (IXHL) Gains Momentum, Closing at 0.61 - DWinneX
Incannex Healthcare (NASDAQ:IXHL) Trading Down 19% – Here’s Why - Defense World
Incannex enters agreement for potential stock sales By Investing.com - Investing.com India
Incannex enters agreement for potential stock sales - Investing.com Australia
IXHL Stock Touches 52-Week Low at $0.64 Amid Market Challenges - Investing.com
Incannex Healthcare Completes Phase 2 Enrollment In Reposa Phase 2/3 Trial Of Ihl-42X, An Oral Once-Daily Treatment For Obstructive Sleep Apnea (Osa) - MarketScreener
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) - TradingView
Revolutionary Once-Daily Pill for Sleep Apnea Hits Major Clinical Trial Milestone - Stock Titan
IXHL stock touches 52-week low at $0.73 amid market challenges - Investing.com
Incannex Healthcare files to sell 65.97M shares of common stock for holders - MSN
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Decrease in Short Interest - The AM Reporter
Incannex Healthcare Repays Convertible Debenture in Full - TipRanks
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
IXHL Stock Touches 52-Week Low at $0.73 Amid Market Challenges - Investing.com Australia
IXHL Stock Touches 52-Week Low at $0.73 Amid Market Challenges By Investing.com - Investing.com South Africa
Incannex Healthcare announces $12.5 million offering - Green Market Report
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules - The Manila Times
Incannex Healthcare Inc. Announces Pricing Of $12.5 Million Private Placement Priced At The Market Under Nasdaq Rules - Marketscreener.com
Incannex Healthcare Inc. Announces $12.5 Million Offering of Common Stock and Series A Warrants - Nasdaq
Can This $12.5M Deal Push Incannex's Sleep Apnea Treatment to Phase 3? - StockTitan
IXHL stock touches 52-week low at $1.09 amid market challenges - Investing.com Australia
Incannex OSA Drug Candidate IHL-42X Sails Through Milestones - Sleep Review
IXHL stock touches 52-week low at $1.49 amid market challenges By Investing.com - Investing.com South Africa
IXHL stock touches 52-week low at $1.49 amid market challenges - Investing.com UK
Incannex Healthcare Limited Reports Quarterly Financials - TipRanks
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025 - The Kingston Whig-Standard
Biotech Earnings Alert: Incannex Secures $50M Financing as R&D Costs Drop 46% - Stock Titan
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates - Defense World
Incannex Healthcare Reports Fiscal Second Quarter Results -February 14, 2025 at 08:49 am EST - Marketscreener.com
Incannex Healthcare Inc. SEC 10-Q Report - TradingView
Incannex Healthcare Appoints Alison Wimms, Ph.D. to its Newly Formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board - Defense World
Incannex Forms Clinical Advisory Board to Guide IHL-42X Sleep Apnea Drug Development - Sleep Review
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board - The Manila Times
Incannex Healthcare Inc. Announces the Appointment of Alison Wimms as an Advisor to Its Newly Formed Ihl-42X Obstructive Sleep Apnea Clinical Advisory Board - Marketscreener.com
Sleep Medicine Pioneer Joins Incannex's Revolutionary OSA Treatment Development - StockTitan
Incannex Healthcare Announces Positive Topline Results from PK Study - Defense World
Incannex Reports Positive Data for OSA Drug Candidate IHL-42X - Sleep Review
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea - The Manila Times
Incannex Reports Strong Results for Sleep Apnea Drug IHL-42X in Key Clinical Study - StockTitan
Incannex Healthcare faces Nasdaq delisting over market value By Investing.com - Investing.com South Africa
Incannex Healthcare faces Nasdaq delisting over market value - Investing.com
Incannex Healthcare Inc Stock (IXHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):